BioCentury
ARTICLE | Clinical News

Array gains after binimetinib meets in Phase III

December 17, 2015 2:33 AM UTC

Array BioPharma Inc. (NASDAQ:ARRY) jumped $0.79 to $4.62 after lead candidate binimetinib ( MEK162) led to an improvement in progression-free survival (PFS) over dacarbazine in the Phase III NEMO trial to treat neuroblastoma Ras viral (v-Ras) oncogene (NRAS)-mutant melanoma. Array remains on track to submit an NDA for binimetinib in 1H16 for the indication.

Patients receiving binimetinib reached a median PFS of 2.8 months compared to 1.5 months for dacarbazine, meeting the trial's primary endpoint (HR=0.62; 95% CI: 0.47, 0.80; p<0.001). Array plans to report additional data from the trial next year. ...